xeloda tablets 150 mg
dksh singapore pte. ltd. - capecitabine - tablet, film coated - 150 mg - capecitabine 150 mg
xeloda tablets 500 mg
dksh singapore pte. ltd. - capecitabine - tablet, film coated - 500 mg - capecitabine 500 mg
erbitux
pharmacy retailing (nz) ltd t/a healthcare logistics - cetuximab 5 mg/ml; ; - solution for infusion - 5 mg/ml - active: cetuximab 5 mg/ml excipient: citric acid monohydrate glycine polysorbate 80 sodium chloride sodium hydroxide water for injection - erbitux is indicated for the treatment of patients with epidermal growth factor receptor (egfr)-expressing, ras wild-type metastatic colorectal cancer · in combination with infusional 5-fluorouracil/folinic acid plus irinotecan · in combination with irinotecan in patients who are refractory to first-line chemotherapy · in first-line in combination with folfox · as a single agent in patients who have failed or are intolerant to oxaliplatin-based therapy and irinotecan-based therapy. (see clinical trials)
avastin concentrate for solution for infusion 100mg4ml
roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 25mg - bevacizumab 25mg
avastin concentrate for solution for infusion 400mg16ml
roche singapore pte. ltd. - bevacizumab - infusion, solution concentrate - 400mg - bevacizumab 400mg
avastin 25mg/ml concentrate for solution for infusion
roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml
avastin 25mg/ml concentrate for solution for infusion
roche diagnostics gmbh - bevacizumab - concentrate for solution for infusion - 25mg/ml
vectibix concentrate for solution for infusion 100 mgvial
amgen biotechnology singapore pte ltd - panitumumab - infusion, solution concentrate - 100 mg/vial - panitumumab 100 mg/vial